Radiotherapy for osteoblastoma: the 25-year institutional experience
Abstract
Background: Osteoblastoma (OB) is a rare benign bone tumor, mainly affecting adolescents and young adults. It's commonly found in the spine and long bones, with a male-to-female ratio of 2:1. Surgery, primarily en bloc resection or curettage, is the main treatment. Radiotherapy (RT) or systemic treatment is considered in specific cases. However, optimal RT strategies remain unclear due to limited and outdated data. This study aims to evaluate RT role, efficacy, and safety in treating OB.
Matrials and methods: The study group was a cohort of consecutive patients with OB treated in our institute that received RT in years 1998–2023. We analyzed indication for RT, irradiated site, RT technique, total dose, dose per fraction, early and late tolerance, and survival.
Results: Thirteen patients meeting the criteria were analyzed. Most were males (10 out of 13) with a median age of 21. Most OBs were within the vertebral column. All patients received definitive RT for unresectable disease and underwent conventionally fractionated RT (1.8–2.0 Gy per fraction) to total doses 40–70.2 Gy. Only mild acute toxicity was observed. No late toxicity was reported. The median follow-up was 118 months. Local progression was observed in four patients, all of whom died.
Conclusions: RT is a valuable option for certain OB patients ineligible for surgery. Seeking treatment at specialized bone tumor centers with RT techniques is crucial due to OB's rarity and the lack of standardized guidelines. Recommended RT doses fall between 50–70 Gy using intensity-modulated techniques in conventional 1.8–2 Gy fractions.
Keywords: osteoblastomabone tumorradiotherapyrare cancerbenign tumor
References
- Atesok KI, Alman BA, Schemitsch EH, et al. Osteoid osteoma and osteoblastoma. J Am Acad Orthop Surg. 2011; 19(11): 678–689.
- Jaffe HL. Benign osteoblastoma. Bull Hosp Joint Dis. 1956; 17(2): 141–151.
- Lichtenstein L. Benign osteoblastoma.A category of osteoid- and bone-forming tumors other than classical osteoid osteoma, which may be mistaken for giant-cell tumor or osteogenic sarcoma. Cancer. 1956; 9(5): 1044–1052, doi: 10.1002/1097-0142(195609/10)9:5<1044::aid-cncr2820090523>3.0.co;2-o.
- Limaiem F, Byerly DW, Mabrouk A, Singh R. Osteoblastoma. StatPearls. StatPearls Publishing, Treasure Island (FL) 2023.
- Boriani S, Capanna R, Donati D, et al. Osteoblastoma of the spine. Clin Orthop Relat Res. 1992(278): 37–45.
- Galgano MA, Goulart CR, Iwenofu H, et al. Osteoblastomas of the spine: a comprehensive review. Neurosurg Focus. 2016; 41(2): E4.
- Berberoglu S, Oguz A, Aribal E, et al. Osteoblastoma response to radiotherapy and chemotherapy. Med Pediat Oncol. 1997; 28(4): 304–309, doi: 10.1002/(sici)1096-911x(199704)28:4<304::aid-mpo11>3.0.co;2-c.
- Mesfin A, Boriani S, Gambarotti M, et al. Can Osteoblastoma Evolve to Malignancy? A Challenge in the Decision-Making Process of a Benign Spine Tumor. World Neurosurg. 2020; 136: 150–156.
- Yamaga K, Kuwamoto S, Tanishima S, et al. An unresectable osteoblastoma of the axis controlled with denosumab. J Orthop Sci. 2024; 29(1): 379–383.
- Kooner P, Ferguson P. The Use of Denosumab in Osteoblastoma of the Metacarpal. J Hand Surg Am. 2019; 44(11): 994.e1–994.e6.
- Strauss SJ, Frezza AM, Abecassis N, et al. ESMO Guidelines Committee, EURACAN, GENTURIS and ERN PaedCan. Electronic address: clinicalguidelines@esmo.org. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(12): 1520–1536.
- Singer JM, Deutsch GP. The successful use of radiotherapy for osteoblastoma. Clin Oncol (R Coll Radiol). 1993; 5(2): 124–125.
- Miszczyk L, Wozniak G, Walichiewicz P, et al. Radiotherapy in the treatment of osteoblastoma — a report of five consecutive cases. Nowotwory. 2004; 54(1): 31–3.
- Capanna R, Ayala A, Bertoni F, et al. Sacral osteoid osteoma and osteoblastoma: a report of 13 cases. Arch Orthop Trauma Surg (1978). 1986; 105(4): 205–210.
- Boriani S, Amendola L, Bandiera S, et al. Staging and treatment of osteoblastoma in the mobile spine: a review of 51 cases. Eur Spine J. 2012; 21(10): 2003–2010.
- Singh DK, Das KK, Mehrotra A, et al. Aggressive osteoblastoma involving the craniovertebral junction: A case report and review of literature. J Craniovertebr Junction Spine. 2013; 4(2): 69–72.
- Bertoni F, Bacchini P, Donati D, et al. Osteoblastoma-like osteosarcoma. The Rizzoli Institute experience. Mod Pathol. 1993; 6(6): 707–716.
- Ozger H, Alpan B, Söylemez MS, et al. Clinical management of a challenging malignancy, osteoblastoma-like osteosarcoma: a report of four cases and a review of the literature. Ther Clin Risk Manag. 2016; 12: 1261–1270.
- Malicki J, Piotrowski T, Guedea F, et al. Treatment-integrated imaging, radiomics, and personalised radiotherapy: the future is at hand. Rep Pract Oncol Radiother. 2022; 27(4): 734–743.
- Gerszten PC, Quader M, Novotny J, et al. Radiosurgery for benign tumors of the spine: clinical experience and current trends. Technol Cancer Res Treat. 2012; 11(2): 133–139.
- Spałek MJ, Teterycz P, Borkowska A, et al. Stereotactic radiotherapy for soft tissue and bone sarcomas: real-world evidence. Ther Adv Med Oncol. 2022; 14: 17588359211070646.
- Wolf RJ, Winkler V, Mattke M, et al. Intensity-modulated radiotherapy for the management of primary and recurrent chordomas: a retrospective long-term follow-up study. Rep Pract Oncol Radiother. 2023; 28(2): 207–216.
- McClelland S, Sun Y, Spratt DE. Spine Patient Optimal Radiosurgery Treatment for Symptomatic Metastatic Neoplasms (SPORTSMEN): a randomized phase II study protocol. Rep Pract Oncol Radiother. 2023; 28(3): 379–388.
- Shaverdian N, Wang PC, Steinberg M, et al. The patient's perspective on stereotactic body radiation therapy (SBRT) vs. surgery for treatment of early stage non-small cell lung cancer (NSCLC). Lung Cancer. 2015; 90(2): 230–233.
- Patel SA, Switchenko JM, Fischer-Valuck B, et al. Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer. Radiat Oncol. 2020; 15(1): 217.
- Byun HK, Han MC, Yang K, et al. Physical and Biological Characteristics of Particle Therapy for Oncologists. Cancer Res Treat. 2021; 53(3): 611–620.
- Attiah M, Tucker AM, Perez-Rosendahl M, et al. Epithelioid Osteoblastoma of the Temporal Bone: A Case Report. World Neurosurg. 2019; 123: 378–382.
- Pompos A, Durante M, Choy H. Heavy Ions in Cancer Therapy. JAMA Oncol. 2016; 2(12): 1539–1540.
- Honda A, Iizuka Y, Imai R, et al. Recurrent lumbar-origin osteoblastoma treated with multiple surgery and carbon ion radiotherapy: a case report. BMC Musculoskelet Disord. 2020; 21(1): 321.